Title:
METHIONINE AMINOPEPTIDASE 2 (METAP2) INHIBITORS FOR TREATING CARDIOVASCULAR OR CEREBROVASCULAR DISORDERS
Document Type and Number:
WIPO Patent Application WO/2011/088055
Kind Code:
A3
Abstract:
The invention generally relates to methods of treating a patient having, and/or at risk of, cardiovascular or cerebrovascular disorders. Such methods may include administering a MetAP2 inhibitor at a dose that does not substantially modulate angiogenesis.
Inventors:
HUGHES THOMAS E (US)
Application Number:
PCT/US2011/020866
Publication Date:
November 03, 2011
Filing Date:
January 11, 2011
Export Citation:
Assignee:
ZAFGEN CORP (US)
HUGHES THOMAS E (US)
HUGHES THOMAS E (US)
International Classes:
A61K31/00; A61K31/192; A61K31/216; A61K31/336; A61K31/366; A61K31/397; A61K31/40; A61K31/404; A61K31/4418; A61K31/455; A61K31/47; A61K31/505; A61K31/7088; A61K45/06; A61P3/06
Domestic Patent References:
| WO2005082349A1 | 2005-09-09 |
Other References:
BRAKENHIELM EBBA ET AL: "Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice", CIRCULATION RESEARCH, vol. 94, no. 12, 25 June 2004 (2004-06-25), pages 1579 - 1588, XP002634162, ISSN: 0009-7330
YOO MEE KIM ET AL: "Assessment of the ant-obesity effects of the TNP-470 analog, CKD-732", J. MOL. ENDOCRIN,, vol. 38, 1 January 2007 (2007-01-01), pages 455 - 465, XP002632891
BRAHN E ET AL: "SUPPRESSION OF CORONARY VASCULITIS IN A MURINE MODEL OF KAWASAKI DISEASE USING AN ANGIOGENESIS INHIBITOR", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 90, no. 1, 1 January 1999 (1999-01-01), pages 147 - 151, XP001180893, ISSN: 1521-6616, DOI: DOI:10.1006/CLIM.1998.4645
MOULTON K S ET AL: "Angiongenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 99, no. 13, 6 April 1999 (1999-04-06), pages 1726 - 1732, XP002985279, ISSN: 0009-7322
WINTER PATRICK M ET AL: "Endothelial alpha(v)beta(3) integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis", ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, vol. 26, no. 9, September 2006 (2006-09-01), pages 2103 - 2109, XP002634163, ISSN: 1079-5642
BERNIER S G ET AL: "Fumagillin class inhibitors of methionine aminopeptidase-2", DRUGS OF THE FUTURE, vol. 30, no. 5, 1 January 2005 (2005-01-01), pages 497 - 508, XP008097519, ISSN: 0377-8282, DOI: DOI:10.1358/DOF.2005.030.05.895807
YOO MEE KIM ET AL: "Assessment of the ant-obesity effects of the TNP-470 analog, CKD-732", J. MOL. ENDOCRIN,, vol. 38, 1 January 2007 (2007-01-01), pages 455 - 465, XP002632891
BRAHN E ET AL: "SUPPRESSION OF CORONARY VASCULITIS IN A MURINE MODEL OF KAWASAKI DISEASE USING AN ANGIOGENESIS INHIBITOR", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 90, no. 1, 1 January 1999 (1999-01-01), pages 147 - 151, XP001180893, ISSN: 1521-6616, DOI: DOI:10.1006/CLIM.1998.4645
MOULTON K S ET AL: "Angiongenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 99, no. 13, 6 April 1999 (1999-04-06), pages 1726 - 1732, XP002985279, ISSN: 0009-7322
WINTER PATRICK M ET AL: "Endothelial alpha(v)beta(3) integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis", ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, vol. 26, no. 9, September 2006 (2006-09-01), pages 2103 - 2109, XP002634163, ISSN: 1079-5642
BERNIER S G ET AL: "Fumagillin class inhibitors of methionine aminopeptidase-2", DRUGS OF THE FUTURE, vol. 30, no. 5, 1 January 2005 (2005-01-01), pages 497 - 508, XP008097519, ISSN: 0377-8282, DOI: DOI:10.1358/DOF.2005.030.05.895807
Attorney, Agent or Firm:
KAVANAUGH, Theresa, C. et al. (Exchange PlaceBoston, MA, US)
Download PDF:
Previous Patent: LED WITH UNIFORM CURRENT SPREADING AND METHOD OF FABRICATION
Next Patent: METHOD AND SYSTEM FOR PRODUCING GRAPHENE AND GRAPHENOL
Next Patent: METHOD AND SYSTEM FOR PRODUCING GRAPHENE AND GRAPHENOL